Previous 10 | Next 10 |
RADNOR, Pa., March 16, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today provided a business update on its clinical development activities and repor...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Anaplan (NYSE: PLAN ) -29% despite Q4 beat . More news on: Anaplan, Inc., Continental Resources, Inc., Nutanix, Inc., Stocks on the move, , Read more ...
RADNOR, Pa., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced it has reached the 100 patient enrollment targe...
RADNOR, Pa., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that management will present a corporate overvi...
TrueCar (NASDAQ: TRUE ) -29% after guidance disappoints. More news on: TrueCar, Inc., BlueLinx Holdings Inc., EyePoint Pharmaceuticals, Inc., Stocks on the move, , Read more ...
RADNOR, Pa., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the upcoming presentation of EEG data from its ...
Enrollment on-track for CDKL5 Deficiency Disorder Phase 3 readout Q3 2020 Two additional late-stage clinical trials planned to initiate in 2020 Company presentation and live webcast at 38th Annual J.P. Morgan Global Healthcare Conference on Thursday, January 16, 2020 at 11:00am PT ...
Are Any Of These Penny Stocks On Your Watch List This Week? When it comes to penny stocks , it may be hard to plan ahead. But then you can’t forget that a few sectors are well-known for giving a preview of what’s to come. In this regard, I’d like to look at a few biotech...
RADNOR, Pa., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), (Nasdaq: MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and other neuropsychiatric...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will h...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law Firm PR Newswire LOS ANGELES , July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing ...
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...